| Literature DB >> 29402218 |
Waseem Abu-Ashour1, Laurie K Twells1,2, James E Valcour2, John-Michael Gamble3,4.
Abstract
BACKGROUND: People with diabetes may be at higher risk for acquiring infections through both glucose-dependent and biologic pathways independent of glycemic control. Our aim was to estimate the association between diabetes and infections occurring in primary care.Entities:
Keywords: CPCSSN; Diabetes; Infection; Matched cohort; Primary care
Mesh:
Year: 2018 PMID: 29402218 PMCID: PMC5800043 DOI: 10.1186/s12879-018-2975-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Baseline Characteristics for 12,845 Patients With and Without Diabetes
| Variable | Diabetes | Non-Diabetes ( | |
|---|---|---|---|
| Age | < 0.001 | ||
| Mean (SD) | 57.5 (15.6) | 43.1 (16.5) | |
| Median (IQR) | 59.0 (20) | 41.0 (26) | |
| Gender n, (%) | |||
| Male | 889 (50.0) | 4435 (40.1) | < 0.001 |
| Female | 890 (50.0) | 6631 (59.9) | < 0.001 |
| Doctor Visits (Mean, SD) | 3.7 (3.9) | 3.3 (3.8) | 0.015 |
| Referral To a Specialist, n (%) | |||
| 0 | 1568 (88.1) | 9927 (89.7) | 0.05 |
| 1 | 133 (7.5) | 755 (6.8) | 0.338 |
| ≥2 | 78 (4.4) | 384 (3.5) | 0.064 |
| Infection before 1-year entry, n (%) | |||
| 0 | 1385 (77.8) | 6261 (56.6) | < 0.001 |
| 1 | 203 (11.4) | 1894 (17.1) | < 0.001 |
| ≥2 | 191 (10.7) | 2911 (26.3) | < 0.001 |
| Lab Tests (Mean, SD) | 14.5 (46.3) | 10.6 (33.2) | < 0.001 |
| Vaccines, n (%) | 251 (14.1) | 1202 (10.9) | < 0.001 |
| Acid-suppressing Medications, n (%) | 306 (17.2) | 983 (8.9) | < 0.001 |
| Respiratory Medications, n (%) | 173 (9.72) | 1140 (10.3) | 0.482 |
| Lipid-lowering Medications, n (%) | 716 (40.2) | 653 (5.9) | < 0.001 |
| Microvascular Disease, n (%) | 29 (1.6) | 23 (0.2) | < 0.001 |
| Macrovascular Disease, n (%) | 76 (4.3) | 111 (1) | < 0.001 |
| Heart failure, n (%) | 19 (1.1) | 16 (0.1) | < 0.001 |
| Fatty Liver, n (%) | 10 (0.6) | 12 (0.1) | < 0.001 |
| Obesity, n (%) | 61 (3.4) | 129 (1.2) | < 0.001 |
| Respiratory Disease, n (%) | 236 (13.3) | 2273 (20.5) | < 0.001 |
| Follow up time, years (Mean, SD) | 4.2 (1.7) | 4.2 (1.7) | 0.788 |
Number of Patients With and Without Diabetes Over the Full and 1-Year Follow-up Periods Experiencing One or More Infections
| Infection Type | Full Follow-up Period | 1-year Follow-up period | ||||
|---|---|---|---|---|---|---|
| Diabetes | Non-Diabetes (n = 11,066) | Diabetes | Non-Diabetes (n = 11,066) | |||
| Any Infection | 1012 (56.9) | 6428 (58.1) | 0.354 | 584 (32.8) | 3500 (31.6) | 0.327 |
| Head & Neck | 118 (6.6) | 817 (7.4) | 0.280 | 39 (2.2) | 298 (2.7) | 0.252 |
| Respiratory | 462 (26.0) | 3266 (29.5) | 0.002 | 210 (11.8) | 1381 (12.5) | 0.445 |
| Gastrointestinal | 151 (8.5) | 694 (6.3) | < 0.001 | 69 (3.9) | 245 (2.2) | < 0.001 |
| Genitourinary | 203 (11.4) | 1172 (10.6) | 0.319 | 93 (5.2) | 438 (4.0) | 0.015 |
| Skin & Soft Tissue | 199 (11.2) | 896 (8.1) | < 0.001 | 78 (4.4) | 269 (2.4) | < 0.001 |
| Musculoskeletal | 185 (10.4) | 1189 (10.7) | 0.692 | 62 (3.5) | 388 (3.5) | 1.000 |
| Viral | 84 (4.7) | 428 (3.9) | 0.100 | 30 (1.7) | 130 (1.2) | 0.091 |
Infections Per 100 Person-Years in Patients With and Without Diabetes Over the Full and 1-year Follow-up Periods
| Infection Type | Full Study Period | 1-year study period | ||||
|---|---|---|---|---|---|---|
| Diabetes | Non-Diabetes | Diabetes | Non-Diabetes | |||
| Any Infection | 42.7 (63.0) | 42.5 (59.9) | 0.895 | 54.7 (99.3) | 50.2 (94.6) | 0.077 |
| Head & Neck | 2.1 (11.5) | 2.2 (9.7) | 0.771 | 2.6 (18.2) | 3.0 (19.5) | 0.318 |
| Respiratory | 13.4 (36.3) | 13.9 (30.0) | 0.589 | 16.2 (52.2) | 16.3 (49.7) | 0.943 |
| Gastrointestinal | 3.4 (15.0) | 2.2 (11.1) | 0.001 | 4.9 (27.9) | 2.7 (19.4) | 0.001 |
| Genitourinary | 4.8 (18.0) | 4.2 (16.5) | 0.148 | 6.9 (33.1) | 4.9 (26.7) | 0.016 |
| Skin & Soft Tissue | 4.1 (15.3) | 2.4 (10.5) | < 0.001 | 5.2 (26.3) | 2.6 (17.4) | < 0.001 |
| Musculoskeletal | 3.7 (14.4) | 3.8 (14.5) | 0.789 | 4.3 (25.1) | 4.0 (22.3) | 0.617 |
| Viral | 1.4 (7.1) | 1.1 (6.6) | 0.083 | 1.7 (13.5) | 1.2 (11.4) | 0.122 |
Odds Ratio (OR) Between Diabetes and Infection Over the Full Follow-up Period: Crude and Adjusted Results
| Type of Infection | Crude OR | 95%CI | Adjusted OR | 95%CI | ||
|---|---|---|---|---|---|---|
| Any Infection | 0.96 | 0.86–1.06 | 0.399 | 1.21 | 1.07–1.37 | 0.002 |
| Head & Neck | 0.90 | 0.74–1.11 | 0.328 | 1.13 | 0.89–1.43 | 0.313 |
| Respiratory | 0.84 | 0.75–0.94 | 0.003 | 1.30 | 1.13–1.48 | < 0.001 |
| Gastrointestinal | 1.38 | 1.15–1.67 | < 0.001 | 1.40 | 1.12–1.75 | 0.003 |
| Genitourinary | 1.10 | 0.94–1.29 | 0.238 | 1.48 | 1.22–1.81 | < 0.001 |
| Skin & Soft Tissue | 1.43 | 1.21–1.69 | < 0.001 | 1.66 | 1.37–2.02 | < 0.001 |
| Musculoskeletal | 0.97 | 0.82–1.14 | 0.714 | 1.05 | 0.87–1.28 | 0.598 |
| Viral | 1.21 | 0.95–1.55 | 0.115 | 1.15 | 0.86–1.54 | 0.351 |
Adjusted for age, sex, smoking, comorbidities (microvascular disease [nephropathy, neuropathy, retinopathy], macrovascular disease [coronary artery disease, peripheral and cerebral vascular disease], heart failure, respiratory disease, dyslipidemia, fatty liver disease, and obesity), medications (acid inhibitors, respiratory system medications, anti-lipids and vaccines) and number of infections in the year prior to enrollment
Odds Ratio (OR) Between Diabetes and Any Infection Recurrence: Crude and Adjusted Results
| Recurrences | Crude OR | 95%CI | P value | Adjusted OR | 95%CI | |
|---|---|---|---|---|---|---|
| ≥1 Infection | 0.96 | 0.86–1.06 | 0.399 | 1.21 | 1.07–1.37 | 0.002 |
| ≥2 Infection | 0.92 | 0.82–1.04 | 0.196 | 1.32 | 1.14–1.52 | < 0.001 |
| ≥3 Infection | 0.99 | 0.86–1.13 | 0.872 | 1.53 | 1.29–1.83 | < 0.001 |
Adjusted for age, sex, smoking, comorbidities (microvascular disease [nephropathy, neuropathy, retinopathy], macrovascular disease [coronary artery disease, peripheral and cerebral vascular disease], heart failure, respiratory disease, dyslipidemia, fatty liver disease, and obesity), medications (acid inhibitors, respiratory system medications, anti-lipids and vaccines) and number of infections in the year prior to enrollment